Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$12.44 -0.7%	$15.68	$8.89 ▼ $24.50	$539.40M	N/A	490,939 shs	153,232 shs
ENOV Enovis	$30.19 -2.3%	$32.87	$28.83 ▼ $49.83	$1.72B	1.7	907,052 shs	407,853 shs
EYE National Vision	$25.28 +0.1%	$21.35	$9.56 ▼ $25.52	$2.00B	1.27	1.91 million shs	1.26 million shs
NVCR NovoCure	$16.55 -1.4%	$17.66	$14.17 ▼ $34.13	$1.84B	0.72	1.12 million shs	264,473 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	-2.34%	-6.14%	-34.36%	+14.53%	+1,252,999,900.00%
ENOV Enovis	-3.15%	-11.05%	-3.01%	-0.68%	-30.93%
EYE National Vision	+1.00%	+2.14%	+17.43%	+121.00%	+99.21%
NVCR NovoCure	-3.62%	-4.11%	-4.33%	+6.06%	-6.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	2.4605 of 5 stars	3.4	1.0	0.0	0.0	1.5	1.7	1.9
EYE National Vision	2.8417 of 5 stars	2.3	2.0	0.0	3.3	3.3	0.8	0.0
NVCR NovoCure	3.5165 of 5 stars	3.4	1.0	0.0	4.5	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$23.44	88.46% Upside
ENOV Enovis	2.80	Moderate Buy	$55.60	84.15% Upside
EYE National Vision	2.56	Moderate Buy	$22.10	-12.59% Downside
NVCR NovoCure	2.71	Moderate Buy	$32.43	95.98% Upside

Current Analyst Ratings Breakdown

Latest BBNX, ENOV, NVCR, and EYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/8/2025	EYE National Vision	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
7/8/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$17.00 ➝ $30.00
7/8/2025	ENOV Enovis	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$48.00 ➝ $46.00
7/8/2025	NVCR NovoCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$65.12M	8.28	N/A	N/A	($5.72) per share	-2.17
ENOV Enovis	$2.11B	0.82	$18.19 per share	1.66	$45.10 per share	0.67
EYE National Vision	$1.85B	1.08	$1.65 per share	15.29	$10.37 per share	2.44
NVCR NovoCure	$621.71M	2.97	N/A	N/A	$3.33 per share	4.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	-$825.49M	-$13.95	N/A	9.46	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
EYE National Vision	-$28.50M	-$0.33	N/A	93.64	3.67	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)

Latest BBNX, ENOV, NVCR, and EYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ENOV Enovis	$0.74	N/A	N/A	N/A	$555.80 million	N/A
8/6/2025	Q2 2025	EYE National Vision	$0.12	N/A	N/A	N/A	$469.21 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/6/2025	Q1 2025	BBNX Beta Bionics	-$0.51	-$0.52	-$0.01	-$0.93	N/A	N/A
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	15.88	14.93
ENOV Enovis	0.52	2.55	1.32
EYE National Vision	0.29	0.54	0.35
NVCR NovoCure	0.27	1.47	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
ENOV Enovis	98.45%
EYE National Vision	N/A
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
ENOV Enovis	2.70%
EYE National Vision	2.70%
NVCR NovoCure	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.36 million	N/A	N/A
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable

BBNX, ENOV, NVCR, and EYE Headlines

Recent News About These Companies

NovoCure (NASDAQ:NVCR) Research Coverage Started at LADENBURG THALM/SH SH

July 11, 2025 | americanbankingnews.com

Ladenburg Thalmann Initiates Coverage of NovoCure (NVCR) with Buy Recommendation

July 9, 2025 | msn.com

NovoCure (NASDAQ:NVCR) Coverage Initiated at LADENBURG THALM/SH SH

July 8, 2025 | marketbeat.com

Summit Trail Advisors LLC Acquires 40,570 Shares of NovoCure Limited (NASDAQ:NVCR)

July 2, 2025 | marketbeat.com

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss

June 30, 2025 | finance.yahoo.com

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

June 30, 2025 | zacks.com

NovoCure Limited (NASDAQ:NVCR) Shares Sold by Taylor Frigon Capital Management LLC

June 30, 2025 | marketbeat.com

Novocure to Report Second Quarter 2025 Financial Results

June 30, 2025 | businesswire.com

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts

June 29, 2025 | marketbeat.com

Demystifying NovoCure: Insights From 4 Analyst Reviews

June 27, 2025 | benzinga.com

NovoCure's (NVCR) "Overweight" Rating Reiterated at Piper Sandler

June 27, 2025 | marketbeat.com

SG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)

June 23, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?

June 18, 2025 | marketbeat.com

What Makes NovoCure (NVCR) a New Buy Stock

June 18, 2025 | zacks.com

GAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)

June 17, 2025 | marketbeat.com

Simon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)

June 16, 2025 | marketbeat.com

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

June 6, 2025 | zacks.com

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

June 2, 2025 | businesswire.com

Novocure data support pancreatic cancer approval, says Wells Fargo

June 2, 2025 | msn.com

Novocure study shows improved pancreatic cancer survival

June 2, 2025 | massdevice.com

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

June 2, 2025 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Enovix Shares Hit 6-Month High; Long-Term Highs to Follow
By Thomas Hughes | July 10, 2025
View Enovix Shares Hit 6-Month High; Long-Term Highs to Follow

BBNX, ENOV, NVCR, and EYE Company Descriptions

Beta Bionics NASDAQ:BBNX

$12.44 -0.09 (-0.72%)

As of 12:20 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Enovis NYSE:ENOV

$30.19 -0.71 (-2.29%)

As of 12:39 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

National Vision NASDAQ:EYE

$25.28 +0.02 (+0.10%)

As of 12:39 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

NovoCure NASDAQ:NVCR

$16.55 -0.24 (-1.45%)

As of 12:39 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time